Skip to content
injectcompass
TechniqueClinical

Understanding the Mounjaro dosing schedule

Mounjaro dosing schedule explained: the 2.5 mg start, the step-up to maintenance doses, and how the pen delivers each. Not medical advice.

SL
Sara Lin
RN, BSN · Author
Medically reviewed by Dr. Maya Okafor
Last updated July 24, 2026
Understanding the Mounjaro dosing schedule

Mounjaro dosing schedule explained: the 2.5 mg start, the step-up to maintenance doses, and how the pen delivers each. Not medical advice.

Key points

  • 01The 2.5 mg starting dose is an introductory dose. The Mounjaro (tirzepatide) prescribing information describes 2.5 mg once weekly for the first four weeks as the starting dose. It is meant to let the body adjust to the medication and to reduce gastrointestinal side effects, and it is not considered a maintenance dose for full effect.
  • 02Step up to 5 mg after four weeks. The prescribing information increases the dose to 5 mg once weekly after four weeks. 5 mg is the first maintenance dose, and many people stay there if tolerability and response are adequate.
  • 03Further steps in 2.5 mg increments. If a further increase is needed, the label raises the dose in 2.5 mg steps, no sooner than every four weeks. The available maintenance doses are 5, 10, and 15 mg, with 7.5 and 12.5 mg as intermediate steps.
  • 04The maximum dose is 15 mg per week. The prescribing information names 15 mg once weekly as the highest recommended dose. A higher dose has no established added benefit per the label and is not recommended.
  • 05The schedule stays once weekly. Tirzepatide is injected once a week regardless of strength, on the same day each week, with or without food. The day can be changed when needed as long as at least three days separate two doses.
  • 06Only the prescriber adjusts the dose. Whether and when to step up is decided solely by the prescribing clinician based on tolerability and goals. Do not change the schedule on your own or skip steps to move faster.
  • 07Each pen delivers one fixed dose. The Mounjaro pre-filled pen is set to a single strength and delivers the whole weekly dose per use. When the dose changes, you receive a pen of the new strength; the dose cannot be dialed on the pen yourself.
  • 08Do not double a missed dose. If a dose is missed, the prescribing information describes taking it within four days (96 hours), otherwise skipping it. Never double up to make up a missed dose. See our guide on a missed dose for more.

Frequently asked questions

What is the Mounjaro dosing schedule?+

The prescribing information describes starting at 2.5 mg once weekly for four weeks, then 5 mg. If needed, further increases follow in 2.5 mg steps no sooner than every four weeks, up to a maximum of 15 mg weekly. Adjustment is decided by the prescribing clinician.

Why does Mounjaro start at 2.5 mg?+

The 2.5 mg dose is described in the label as an introductory dose that lets the body adjust and eases nausea and other gastrointestinal effects. It is not considered a maintenance dose for full effect.

What is the highest Mounjaro dose?+

The prescribing information names 15 mg once weekly as the highest recommended dose. The maintenance doses are 5, 10, and 15 mg, with 7.5 and 12.5 mg as intermediate steps for people who need a slower increase.

Can I set the dose on the pen myself?+

No. The Mounjaro pre-filled pen is set to a single strength and delivers the whole weekly dose. When the dose changes, the clinic prescribes a pen of the new strength. Our guide on how to use the Mounjaro pen shows how it works.

What if I miss a dose?+

The prescribing information describes taking a missed dose within four days (96 hours). If more time has passed, skip it and inject the next one on the usual day. Never double up. See our guide on a missed dose for details.

Sources

  1. Eli Lilly. Mounjaro (tirzepatide) Prescribing Information (US label).
  2. European Medicines Agency. Mounjaro (tirzepatide) Summary of Product Characteristics.
  3. Frid AH et al. 2016. New Insulin Delivery Recommendations. Mayo Clinic Proceedings 91(9):1231-1255.